RECORDATI ORD/ IT0003828271 /
| 2024-11-08 5:35:52 PM | Chg. -0.55 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 51.50EUR | -1.06% | 825,110 Turnover: 41.61 mill. |
50.45Bid Size: 53 | 51.95Ask Size: 9 | 10.61 bill.EUR | 2.33% | 27.21 |
GlobeNewswire
2021-03-23
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S AN...
GlobeNewswire
2021-02-22
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBI...
GlobeNewswire
2021-01-29
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
GlobeNewswire
2020-11-30
RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEA...
GlobeNewswire
2020-10-29
RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NE...
GlobeNewswire
2020-10-01
RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P....
GlobeNewswire
2020-09-21
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
GlobeNewswire
2020-07-30
RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET IN...
GlobeNewswire
2020-06-17
RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S D...
GlobeNewswire
2020-05-07
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
GlobeNewswire
2020-04-29
RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
GlobeNewswire
2020-03-18
RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY D...
GlobeNewswire
2020-03-18
BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). ...
GlobeNewswire
2020-02-14
RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBIT...
GlobeNewswire
2019-10-31
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING IN...
GlobeNewswire
2019-10-23
RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED
GlobeNewswire
2019-07-30
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
GlobeNewswire
2019-07-12
RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)
GlobeNewswire
2019-06-24
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
GlobeNewswire
2019-05-08
RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED
